 |
Kekst CNC is handling the Chapter 11 filing of Buffalo-based Athenex Inc., a biopharmaceutical company focused on cancer treatments.
The bankruptcy move, which follows the completion of a strategic review, is designed to facilitate the sale of its primary businesses.
Athenex CEO Johnson Lau said the company sought to be a leader in bringing innovative cancer treatments to the market and improving patient health outcomes.
It succeeded in gaining regulatory approval for tirbanibulin ointment in the US, Taiwan and some EU countries but received a regulatory setback from the US Food and Drug Administration for its oral paclitaxel product.
“This significant regulatory setback coupled with challenging biotech markets and the difficult economic environment, put tremendous pressure on our ability to continue to fund our business,” said Lau.
The company’s manufacturing plant in Clarence, NY, will continue to operate for at least 90 days to provide a supply of tirbanibulin to its commercial customers.
Lau’s goal is to identify purchases who will continue to develop Athenex’s drug candidates.
Kekst CNC’s Daniel Yunger, Wendi Kopsick, Rich Goldman, and Mark Fallati are working the Chapter 11 filing.
Publicis Groupe owns Kekst CNC.
Edelman handles Viking Holdings, the river and ocean luxury cruise line that plans to raise $1B via an IPO priced in the $21 to $25 per share range.
Teneo is handling the initial public offering of CVC Capital Partners, one of Europe’s largest private equity firms with nearly $200B in assets under management.
Brunswick Group represents Endeavor Group Holdings as it agrees to go private via its acquisition by Silver Lake technology investment firm, which is handled by Edelman Smithfield.
Tod Donhauser, a nine-year veteran of Edelman, has joined H/Advisors Abernathy as managing director and head of its San Francisco office.
Intelligent Group Ltd, a Hong Kong-based financial PR firm, has priced its initial public offering of 1.9M shares at $4, which is the low end of the $4 to $5 range.
Have a comment? Send it to 
No comments have been submitted for this story yet.